Profile data is unavailable for this security.
About the company
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
- Revenue in USD (TTM)8.92m
- Net income in USD-32.64m
- Incorporated2015
- Employees36.00
- LocationMereo BioPharma Group PLCOne Cavendish Place, Fourth FloorLONDON W1G0QFUnited KingdomGBR
- Websitehttps://www.mereobiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocugen Inc | 6.04m | -63.08m | 409.15m | 65.00 | -- | 10.06 | -- | 67.79 | -0.2616 | -0.2616 | 0.0247 | 0.1581 | 0.0697 | -- | -- | 92,861.54 | -72.85 | -83.56 | -91.66 | -97.79 | -- | -- | -1,045.03 | -2,921.94 | -- | -- | 0.0646 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Harrow Inc | 130.19m | -24.41m | 410.43m | 315.00 | -- | 5.76 | -- | 3.15 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| ADC Therapeutics SA | 68.62m | -227.23m | 413.61m | 273.00 | -- | -- | -- | 6.03 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Contineum Therapeutics Inc | 50.00m | 22.72m | 413.62m | 31.00 | 17.49 | -- | 18.02 | 8.27 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 414.92m | 240.00 | -- | -- | -- | 1.81 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 417.26m | 126.00 | -- | -- | -- | 3.16 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Neurogene Inc | 0.00 | -36.32m | 418.13m | 91.00 | -- | 2.24 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 423.84m | 145.00 | -- | 1.64 | -- | 21.15 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Mereo BioPharma Group plc - ADR | 8.92m | -32.64m | 425.02m | 36.00 | -- | 5.39 | -- | 47.62 | -0.2614 | -0.2614 | 0.0714 | 0.5621 | 0.0756 | -- | 1.06 | 247,915.30 | -27.63 | -- | -38.33 | -- | 73.75 | -- | -365.71 | -- | -- | -- | 0.1389 | -- | -100.00 | -- | -368.73 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -66.39m | 432.90m | 58.00 | -- | 3.09 | -- | -- | -2.69 | -2.69 | 0.00 | 4.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0153 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Annexon Inc | 0.00 | -134.24m | 432.92m | 71.00 | -- | 1.49 | -- | -- | -1.78 | -1.78 | 0.00 | 3.20 | 0.00 | -- | -- | 0.00 | -46.07 | -44.06 | -49.49 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 437.49m | 265.00 | -- | 1.49 | -- | 6.30 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Taysha Gene Therapies Inc | 15.45m | -111.57m | 437.62m | 52.00 | -- | 5.84 | -- | 28.32 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Cibus Inc | 1.82m | -267.63m | 439.34m | 183.00 | -- | 1.24 | -- | 241.79 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| Nkarta Inc | 0.00 | -116.20m | 440.42m | 150.00 | -- | 0.9297 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 440.76m | 285.00 | -- | 1.53 | -- | 190.72 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Data as of May 10 2024. Currency figures normalised to Mereo BioPharma Group PLC's reporting currency: US Dollar USD
53.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 15 Apr 2024 | 13.55m | 9.67% |
| Adage Capital Management LPas of 24 Jan 2024 | 10.05m | 7.17% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2023 | 9.78m | 6.98% |
| Mangrove Partnersas of 31 Dec 2023 | 8.75m | 6.24% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 7.98m | 5.70% |
| Suvretta Capital Management LLCas of 31 Dec 2023 | 7.37m | 5.26% |
| 683 Capital Management LLCas of 31 Dec 2023 | 6.20m | 4.42% |
| Alkeon Capital Management LLCas of 31 Dec 2023 | 4.24m | 3.02% |
| Tejara Capital Ltd.as of 31 Dec 2023 | 3.71m | 2.65% |
| Clearline Capital LPas of 31 Dec 2023 | 3.33m | 2.37% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
